Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Sponsor: Kirby Institute
Summary
Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-05
Completion Date
2027-03
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
12 weeks of weekly subcutaneous semaglutide injection
12 weeks of subcutaneous semaglutide administered once weekly, starting at 0.25 mg once weekly, titrated as tolerated up to 1.0 mg over the 12-week study period.
Locations (5)
Kirketon Road Centre
Darlinghurst, New South Wales, Australia
Rankin Court Treatment Centre, St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Alcohol & Drug Service, Metro Health North Brisbane
Brisbane, Queensland, Australia
Drug and Alcohol Services, South Australia
Morphett Vale, South Australia, Australia
Next Step Drug and Alcohol Services
East Perth, Western Australia, Australia